The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Simone Bersini
Project Title: A transcriptomic aging clock for human brain endothelial cells
Date: November 20, 2026 at 10:44 am
Request ID:
Aim 1: define an endothelial cell signature of genes related to accelerated aging and alzheimer disease
Aim 2:
Aim 3:
Aim 4:
Investigator: Ehsan Adeli
Project Title: CSF proteomic markers and longitudinal brain structure in older adults
Date: November 19, 2026 at 4:17 pm
Request ID:
Aim 1: Test, in an independent cohort, whether a pre-registered CSF proteomic marker predicts the rate of hippocampal and AD-signature cortical atrophy in amyloid-positive older adults beyond CSF Abeta42, p-tau, age, sex, APOE and clinical stage.
Aim 2: Assess specificity: compare the association in AD-vulnerable regions with a control region, and in amyloid-positive with amyloid-negative participants.
Aim 3: Assess robustness of the association to adjustment for CSF neurodegeneration markers (NfL, neurogranin) and clinical stage.
Aim 4:
Investigator: Qing Wang
Project Title: Normative Modeling of g-DBSI Diffusion MRI Microstructure to Map Individual Deviations Across the Alzheimer Disease Continuum
Date: November 19, 2026 at 1:19 pm
Request ID:
Aim 1: Build a normative model of regional g-DBSI microstructure as a function of age and sex in cognitively unimpaired, amyloid-negative (CDR 0) participants, with scanner and protocol modeled as batch effects, and test its calibration in held-out reference participants.
Aim 2: Compute individual regional deviation z-scores for amyloid-positive CDR 0, CDR 0.5 and CDR ≥ 1 participants, and test how the extent, location and type (isotropic vs anisotropic) of deviations change across clinical stages and differ between individuals.
Aim 3: Validate deviation scores against amyloid PET, tau PET and fluid biomarkers, and test whether baseline deviation burden predicts CDR progression and cognitive decline beyond age, APOE ε4 and amyloid status.
Aim 4:
Investigator: Carlos Cruchaga
Project Title: Plasma tau species and multi-platform proteomic signatures of neuropathology and progression across the Alzheimer’s disease continuum
Date: November 19, 2026 at 9:37 am
Request ID: D2673
Aim 1: Define the overlap of participants and samples across the NULISA CNS panels, SomaScan and Olink datasets, and harmonize sample identifiers, visit dates and technical covariates across platforms.
Aim 2: Relate plasma tau species and other plasma proteins to neuropathology (AD pathology and co-pathologies) and determine how many years before death they reflect and predict autopsy findings.
Aim 3: Test whether baseline levels and trajectories of plasma p-tau species and other proteins differ between stable controls, progressors and AD cases, and predict clinical onset and rate of decline.
Aim 4: Compare tau species between NULISA panels and with SomaScan and Olink measurements of the same samples, and benchmark them against CSF biomarkers and amyloid/tau PET.
Investigator: Yuhu Zhang
Project Title: Vascular Imaging Markers and Longitudinal Tau PET Change
Date: November 10, 2026 at 12:52 am
Request ID:
Aim 1: Determine whether baseline white matter hyperintensity (WMH) burden is associated with the rate of subsequent tau-PET accumulation, and test whether APOE4 modifies this relationship.
Aim 2: Determine whether this relationship is specific to particular brain regions.
Aim 3:
Aim 4:
Investigator: Siyi Yu
Project Title: Structural–Functional Brain Aging Phenotypes and Molecular Signatures of Cognitive Resilience Across the Alzheimer’s Disease Continuum
Date: November 8, 2026 at 3:47 am
Request ID:
Aim 1: To derive and validate structural brain aging (zPAD) and functional maintenance (zBM) metrics from T1 MRI and rs-fMRI and characterize their dissociation across biomarker-defined Alzheimer’s disease stages.
Aim 2: To test whether functional maintenance predicts pathology-adjusted cognitive resilience, longitudinal cognitive decline, and clinical progression independently of structural aging and established AD biomarkers.
Aim 3: To identify plasma/CSF proteomic and metabolomic signatures associated with preserved functional brain organization and favorable cognitive trajectories, with pathway analysis and validation where feasible.
Aim 4:
Investigator: Greg Zaharchuk
Project Title: Evaluating MRI-Based Tau Prediction Across the Alzheimer’s Disease Spectrum
Date: October 31, 2026 at 10:50 am
Request ID: D2672
Aim 1: Improve and validate deep learning models for MRI-based tau prediction. Specifically, improve the ability of our existing model to predict regional tau burden using self-supervised pre-training, additional imaging sequences, demographic and plasma biomarker information, and different architectures.
Aim 2: Evaluate similar models to predict both future tau and risk of cognitive decline.
Aim 3:
Aim 4:
Investigator: Yize Zhao
Project Title: MRI-derived Surrogates to Improve Genetic Discovery of Regional Tau-PET in Alzheimer’s Disease
Date: October 30, 2026 at 5:09 pm
Request ID: D2671
Aim 1: Identify common genetic variants associated with regional flortaucipir tau-PET burden, prioritizing temporal meta-regions, entorhinal cortex and inferior temporal cortex.
Aim 2: Develop MRI-derived tau surrogates using measured PET and tabular structural MRI, with genotype-eligible PET participants reserved for genetic analysis.
Aim 3: Evaluate whether MRI surrogates in separately authorized UK Biobank participants improve precision and detection of measured tau-PET associations without replacing observed PET.
Aim 4:
Investigator: Hui, Sai Kam
Project Title: Surface informed modelling of tau propagation and cognitive change in aging
Date: October 29, 2026 at 4:01 am
Request ID:
Aim 1: Our current research is focused on elderly individuals with impaired cognitive functions, aiming to utilize a modeling framework to describe the spatial and temporal propagation characteristics of the pathological processes of Alzheimer’s disease.
Aim 2: Rather than considering amyloid-β and tau solely as baseline predictors, our goal is also to model how pathological burden evolves across brain regions over time.
Aim 3:
Aim 4:
Investigator: Dandan Qiu
Project Title: Spatiotemporal flow-driven joint state-space modeling for multimodal Alzheimer’s disease progression prediction
Date: October 26, 2026 at 10:28 pm
Request ID:
Aim 1: Develop a time-aware state-space model to capture longitudinal AD dynamics from irregularly sampled visits, using time-interval encoding to learn temporal dependencies across variable follow-up schedules.
Aim 2: Extract regional features from T1-weighted structural MRI (sMRI) and use cognitive assessments to identify and enhance clinically relevant brain regions, capturing spatial patterns of AD-related changes.
Aim 3: Integrate sMRI with other modalities, including functional MRI, PET imaging, CSF and blood biomarkers, genetic data, and clinical measures, to learn complementary cross-modal relationships in AD progression.
Aim 4: Develop and validate multimodal survival models, including DeepHit-based approaches, to predict CN-to-MCI and MCI-to-AD conversion risks and timing while accounting for right censoring, and assess external generalizability using BIOCARD.